Antonilli S, Marklund A, Entrop J, Dietrich CE, Glimelius I, El-Galaly TC, Fosså A, Holte H, Smedby KE, Smeland KB, Eloranta S(2026) Impact of Intensified Chemoimmunotherapy Regimens in Aggressive Non-Hodgkin Lymphoma on Reproduction Patterns Eur J Haematol(in press) DOI 10.1111/ejh.70303, PubMed 42639856
Arffman M, Meriranta L, Jørgensen J, Karjalainen-Lindsberg ML, Beiske K, Pedersen M, Drott K, Fluge Ø, Jyrkkiö S, Brown P, Holte H, Leppä S(2026) A targeted circulating tumor DNA landscape of copy number aberrations in large B-cell lymphomas Leukemia, 40(7), 1381-1391 DOI 10.1038/s41375-026-02955-w, PubMed 42020781
Dreyling M, Doorduijn J, Giné E, Jerkeman M, Walewski J, Hutchings M, Mey U, Riise J, Trneny M, Vergote VKJ, Shpilberg O, da Silva MG, Leppä S, Jiang L, Stilgenbauer S, Kerkhoff A, Jachimowicz RD, Heß G, Meerten TV, Wirths S, Herhaus P, Novak U, Dierlamm J, Hänel M, Hanoun C, Sonnevi K, Visco C, Donnarumma D, Ferreri AJM, Patti Cet al.(2026) Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network Lancet, 407(10542), 1953-1967 DOI 10.1016/S0140-6736(26)00362-4, PubMed 42134356
